LTR Pharma Limited (AU:LTP) has released an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
LTR Pharma Limited’s Director, Lee Rodne, has been granted 100,000 unlisted options at an exercise price of $2.52, set to expire in December 2028. This change reflects shareholder approval during the company’s 2024 Annual General Meeting. Such updates may influence investor perceptions and market activity around LTR Pharma’s stock.
For further insights into AU:LTP stock, check out TipRanks’ Stock Analysis page.